In it, the paper wrote that BfArM “should be the one to take action and request that doctors in Germany today better educate their patients.”
And so it did. On July 5, the FDA-equivalent agency, in cooperation with 28 German manufacturers and distributors of finasteride, including Merck & Company subsidiary MSD Sharp & Dohme GmbH, informed doctors and pharmacists that:
—
“Patients should be aware of the risk of sexual dysfunction when starting finasteride therapy. Patients should also be informed that, based on individual patient case reports
,
sexual dysfunction
may persist for m
ore
than 10 years after discontinuation of the therapy.”